XHKG
9997
Market cap1.26bUSD
Jul 17, Last price
8.42HKD
1D
1.81%
1Q
22.92%
IPO
-71.74%
Name
Kangji Medical Holdings Ltd
Chart & Performance
P/E
15.61
P/S
9.00
EPS
0.49
Div Yield, %
18.27%
Shrs. gr., 5y
2.75%
Rev. gr., 5y
14.91%
Revenues
1.01b
+8.92%
Net income
581m
+15.36%
CFO
560m
+33.48%
Dividend
May 29, 20241.5386 HKD/sh
Earnings
Aug 18, 2025
Profile
Kangji Medical Holdings Limited, through its subsidiaries, designs, develops, manufactures, and sale of minimally invasive surgical instruments and accessories in China. It offers disposable trocars, polymer ligation clips, disposable electrocoagulation forceps, ultrasonic scalpels, and other types of disposable hand-held instruments; and reusable trocars, reusable forceps, and other reusable products. The company's products are used in obstetrics and gynecology, general surgery, urology, and thoracic surgery specialties. It primarily sells products to a network of distributors. The company was founded in 2004 and is headquartered in Hangzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | 1,008,610 8.92% | 926,023 17.76% | 786,367 13.92% | |||||
Cost of revenue | 468,574 | 482,489 | 341,403 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | 540,036 | 443,534 | 444,964 | |||||
NOPBT Margin | 53.54% | 47.90% | 56.58% | |||||
Operating Taxes | 113,556 | 136,476 | 101,970 | |||||
Tax Rate | 21.03% | 30.77% | 22.92% | |||||
NOPAT | 426,480 | 307,058 | 342,994 | |||||
Net income | 581,438 15.36% | 504,021 5.28% | 478,735 4.80% | |||||
Dividends | (1,647,334) | (216,349) | (179,947) | |||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | (43,177) | (16,580) | (391,918) | |||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 3,214 | 6,107 | 6,696 | |||||
Long-term debt | 3,816 | 81,873 | 91,342 | |||||
Deferred revenue | 636 | |||||||
Other long-term liabilities | 28,490 | |||||||
Net debt | (1,810,362) | (2,741,775) | (2,867,915) | |||||
| Cash flow | ||||||||
Cash from operating activities | 560,098 | 419,615 | 319,313 | |||||
CAPEX | (55,293) | (86,821) | (75,697) | |||||
Cash from investing activities | 1,040,501 | (391,696) | (369,983) | |||||
Cash from financing activities | (1,695,521) | (243,532) | (472,792) | |||||
FCF | 465,130 | (143,640) | 123,211 | |||||
| Balance | ||||||||
Cash | 1,242,505 | 2,688,037 | 2,829,516 | |||||
Long term investments | 574,887 | 141,718 | 136,437 | |||||
Excess cash | 1,766,962 | 2,783,454 | 2,926,635 | |||||
Stockholders' equity | 2,628,895 | 1,484,441 | 1,331,396 | |||||
Invested Capital | 893,939 | 2,503,395 | 2,394,424 | |||||
ROIC | 25.11% | 12.54% | 13.89% | |||||
ROCE | 20.30% | 10.87% | 11.72% | |||||
| EV | ||||||||
Common stock shares outstanding | 1,175,750 | 1,172,402 | 1,207,994 | |||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | 567,315 | 476,488 | 466,374 | |||||
EV/EBITDA | ||||||||
Interest | 2,257 | 1,875 | ||||||
Interest/NOPBT | 0.51% | 0.42% | ||||||